Prognosis and Management of Advanced Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors (G3 NETs): A NET-CONNECT Study Performed in Four Expert Centers
Introduction: G3 NETs are rare tumors with poorly defined prognosis and management.
Aim(s): Describe a retrospective cohort of patients with advanced digestive G3 NETs and depict their prognosis and treatment.
Materials and methods: Patients with advanced digestive G3 NET were included from 4 expert centers. Central pathological review was performed. Response rates (RR) to the two first treatment lines (primary endpoint) was analyzed depending on the type of treatment: neuroendocrine carcinoma (NEC)-like, alkylating agent (temozolomide or streptozotocin) (ALK), or somatostatin analogs (SSAs). Factors associated with RR and overall survival (OS) were assessed using logistic or Cox regression models, respectively.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.